Recurrent Malignant Mesothelioma Clinical Trial
Official title:
A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in Patients With Malignant Pleural Mesothelioma
Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung
Status | Completed |
Enrollment | 55 |
Est. completion date | |
Est. primary completion date | June 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed malignant pleural mesothelioma - Epithelial - Sarcomatous - Biphasic - Measurable or nonmeasurable disease - Not amenable to extrapleural pneumonectomy - No known CNS metastases - Performance status - Zubrod 0-1 - WBC at least 3,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - SGOT or SGPT no greater than 1.5 times ULN (5 times ULN if liver involvement of tumor) - Creatinine no greater than 2 times ULN - No gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation - No active peptic ulcer disease - No intractable nausea or vomiting - Must be able to swallow and/or receive enteral medications via gastrostomy feeding tube - No known history of the following: - Dry eye syndrome - Sjogren's syndrome - Keratoconjunctivitis sicca - Exposure keratopathy - Fuch's dystrophy - Other active disorders of the cornea - Not pregnant or nursing - Fertile patients must use effective contraception - No HIV-positive patients receiving combination antiretroviral therapy - No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer that is in complete remission - No prior biologic therapy for this tumor - No prior chemotherapy for this tumor - See Disease Characteristics - At least 3 weeks since prior radiotherapy and recovered - See Disease Characteristics - At least 4 weeks since prior major surgery (e.g., thoracotomy or laparotomy), excluding minor surgeries (e.g., mediastinoscopy, thoracoscopy, or minor biopsies) - Recovered from prior surgery - No prior surgical procedures affecting absorption - No prior investigational anticancer agents for this tumor |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Southwest Oncology Group | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival rate | Erlotinib hydrochloride will not be of further interest if the true one-year survival rate is 35% or less, but of considerable interest if 55% or more. | 1 year | No |
Primary | RECIST response rate | Up to 3 years | No | |
Primary | Association between EGFR expression with survival and response | Up to 3 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00025207 -
Gefitinib in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00107432 -
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
|
Phase 2 | |
Completed |
NCT00027703 -
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
|
Phase 2 | |
Terminated |
NCT00028782 -
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
|
N/A | |
Recruiting |
NCT04213794 -
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients
|
Early Phase 1 | |
Completed |
NCT01503177 -
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
|
Phase 1 | |
Completed |
NCT00243074 -
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT01126346 -
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
|
N/A | |
Withdrawn |
NCT01325753 -
Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
|
N/A | |
Completed |
NCT00459862 -
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
Active, not recruiting |
NCT01064648 -
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 1/Phase 2 | |
Completed |
NCT00365053 -
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
|
Phase 2 | |
Terminated |
NCT01861301 -
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
|
Phase 2 | |
Completed |
NCT00392444 -
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
|
Phase 2 | |
Completed |
NCT00309946 -
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00030498 -
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
|
Phase 1 | |
Recruiting |
NCT03420963 -
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT01105390 -
AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
|
Phase 2 |